1. Cost-effectiveness of adjuvant atezolizumab versus best supportive care in the treatment of patients with resectable early-stage non-small cell lung cancer and overexpression of PD-L1. (31st December 2023) Authors: Escudero-Vilaplana, Vicente; Collado-Borrell, Roberto; De Castro, Javier; Insa, Amelia; Martínez, Alex; Fernández, Elena; Sullivan, Ivana; Flores, Andrés; Arrabal, Natalia; Carcedo, David; Manzaneque, Alba Journal: Journal of medical economics Issue: Volume 26:Number 1(2023) Page Start: 445 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗